Astellas Pharma US, Inc.
=
Northbrook
Illinois
60062
United States
637 articles with Astellas Pharma US, Inc.
-
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
-
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
9/12/2022
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer.
-
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
9/12/2022
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK) today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer.
-
Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
9/5/2022
Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause.
-
Despite being the largest minority group in the United States, the contributions of disabled people are remarkedly underreported in the life sciences industry.
-
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
-
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
8/18/2022
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted the company's New Drug Application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.
-
Two patients receiving Novartis' SMA gene therapy Zolgensma have died from acute liver failure, the company reported Thursday.
-
Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond Medicine
8/8/2022
Astellas Pharma US, Inc. ("Astellas") today announced the winner of the sixth annual C 3 (Changing Cancer Care) Prize, a global challenge that funds and advances the best non-treatment ideas to improve cancer care for patients.
-
Astellas Announces Management Structure - Aug 02, 2022
8/2/2022
Astellas Pharma Inc. announced the following changes to its management structure effective October 1, 2022.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
-
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
7/26/2022
Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
-
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
7/26/2022
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck's anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
-
Astellas Unveils Plans to Open New Biotech Campus in South San Francisco
7/22/2022
Astellas Pharma Inc. announced plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center.
-
Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.
-
Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.
-
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
7/5/2022
Mogrify Limited and Astellas Pharma Inc. announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
-
Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.
-
The FDA has placed Astellas Pharma's Phase I/II FORTIS trial on clinical hold after one of its study participants experienced a serious adverse event.